BioSpace News Archive

City of Hope, a world-renowned cancer research and treatment center, has identified how cancer cells in patients with early-stage breast cancer change and become resistant to hormone or combination therapies, according to a new study published in Nature Cancer.

A human genetic mechanism hijacked by SARS-CoV-2, the coronavirus behind the COVID-19 pandemic, to help it spread also makes it vulnerable to a new class of drug candidates, a new study finds.

Smisson-Cartledge Biomedical LLC, an ISO 13485:2016 certified manufacturer of the ThermaCor 1200 Rapid Infuser technology for use in a broad spectrum of medical procedures, announced that John E Hart has been named as President and Chief Executive Officer to lead the company.

PathAI, a global provider of AI-powered technology applied to pathology, today announced the presentation of new data describing improved digital assessment of nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC).

As America approaches the tail end of the COVID-19 pandemic, a quiet epidemic has emerged that has the potential to affect as many as 476,000 citizens before the year is out.

Seraphina Therapeutics, Inc., a health and wellness company dedicated to advancing global health through the discovery and development of beneficial essential fatty acids and micronutrients, today announced that it has achieved Generally Recognized as Safe (GRAS) status for its revolutionary FA15™ ingredient. FA15™ has been approved as a food ingredient that can be used daily, up to 245 mg per day.

Abbas Hussain (56, British citizen) has a successful and international career of more than 30 years as an executive in the healthcare sector. From 2008 to 2017, Abbas Hussain held various leadership positions for the British pharmaceutical group GlaxoSmithKline, most recently as Global President Pharmaceuticals and Vaccines for five years

The start of summer means more tank tops and shorts, and for some people, a pesky new skin condition they may not have noticed before.

Otolith Labs, launched at the Halcyon Incubator, announced today it has received U.S. Food and Drug Administration (FDA) BREAKTHROUGH DEVICE designation for its medical device that is designed to be prescribed by physicians for the treatment of vertigo.

Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that it has entered into a definitive agreement to acquire Twistle, Inc.